Tsai WC, et al. - In areas of higher HBV endemicity, researchers intended to determine if introduction of tenofovir disoproxil fumarate (TDF)-containing combination antiretroviral therapy (cART) has improved the outcome of HIV/HBV-coinfected patients. Between 2007 and 2015, medical records of newly diagnosed antiretroviral-naïve HIV-infected patients were retrospectively reviewed. Findings suggested that the adverse impact of chronic HBV infection on the survival observed in the pre-TDF era has significantly decreased among HIV/HBV-coinfected patients vs HIV-monoinfected patients in the era of TDF-containing cART. The adjusted hazard ratio for mortality in multivariate Cox proportional-hazards regression analysis among HIV/HBV-coinfected patients vs HIV-monoinfected patients was 2.79 in pre-TDF era and 1.11 in post-TDF era.